Rett Syndrome (RTT) is an Autism Spectrum Disorder (ASD) of known monogenic cause. It represents one of the leading causes of intellectual and developmental disabilities in females. RTT is caused by mutations or duplications of the gene encoding MeCP2, a methyl DNA binding protein thought to modulate global gene expression. Mice with loss of function of MeCP2 (knock-out) have a range of physiological and neurological abnormalities that mimic the human syndrome. Despite the fact that most RTT-causing mutations are clustered at the methyl-CpG binding domain of MeCP2, it is not known if disruption of methyl-CpG recognition alone is sufficient to cause RTT. Moreover, the mechanisms by which MeCP2 dysfunction leads to RTT remain poorly understood. Recently, we have developed a knock-in mouse carrying a missense mutation of MeCP2 at Threonine 158 (T158A). T158 is located at the methyl-CpG binding domain of MeCP2 and is the most common missense mutation associated with human patients. Preliminary studies suggest T158A mutation impairs the ability of MeCP2 to recognize methylated DNA. In addition, T158A knock-in mice appear to show similar symptoms to MeCP2 knock-out mice. Thus, within the scope of this New Program Development Award, we plan to focus on the following specific aims: 1) Phenotypic characterication of the MeCP2 T158A knock-in mice in comparison to MeCP2 knock-out mice. 2) Dissection of the molecular and cellular functions of MeCP2 with MeCP2 T158A knock-in mice. In the long run, we hope to not only gain insights into the pathogenic mechanisms of RTT, but also uncover therapies and cures for ASD.

Public Health Relevance

Current treatment options for ASD are limited, and clinical progress has been slow due to a poor understanding of ASD etiology. At present, Rett Syndrome is the only ASD with a known cause. Thus, understanding the pathogenic basis of RTT will not only shed light on other ASD, but also improve methods for the diagnosis and treatment of other intellectual and developmental disabilities.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Center Core Grants (P30)
Project #
5P30HD026979-24
Application #
8523942
Study Section
Special Emphasis Panel (ZHD1-MRG-C)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
24
Fiscal Year
2013
Total Cost
$64,742
Indirect Cost
$42,175
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Kohls, Gregor; Antezana, Ligia; Mosner, Maya G et al. (2018) Altered reward system reactivity for personalized circumscribed interests in autism. Mol Autism 9:9
Yerys, Benjamin E; Herrington, John D; Bartley, Gregory K et al. (2018) Arterial spin labeling provides a reliable neurobiological marker of autism spectrum disorder. J Neurodev Disord 10:32
Maddox, Brenna B; Cleary, Patrick; Kuschner, Emily S et al. (2018) Lagging skills contribute to challenging behaviors in children with autism spectrum disorder without intellectual disability. Autism 22:898-906
Chapman, Kimberly A; Ostrovsky, Julian; Rao, Meera et al. (2018) Propionyl-CoA carboxylase pcca-1 and pccb-1 gene deletions in Caenorhabditis elegans globally impair mitochondrial energy metabolism. J Inherit Metab Dis 41:157-168
Yerys, Benjamin E; Herrington, John D; Satterthwaite, Theodore D et al. (2017) Globally weaker and topologically different: resting-state connectivity in youth with autism. Mol Autism 8:39
Parish-Morris, Julia; Liberman, Mark Y; Cieri, Christopher et al. (2017) Linguistic camouflage in girls with autism spectrum disorder. Mol Autism 8:48
Glauser, Tracy A; Holland, Katherine; O'Brien, Valerie P et al. (2017) Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy. Ann Neurol 81:444-453
Herrington, John D; Maddox, Brenna B; McVey, Alana J et al. (2017) Negative Valence in Autism Spectrum Disorder: The Relationship Between Amygdala Activity, Selective Attention, and Co-occurring Anxiety. Biol Psychiatry Cogn Neurosci Neuroimaging 2:510-517
Monnerie, Hubert; Romer, Micah; Jensen, Brigid K et al. (2017) Reduced sterol regulatory element-binding protein (SREBP) processing through site-1 protease (S1P) inhibition alters oligodendrocyte differentiation in vitro. J Neurochem 140:53-67
Bangasser, D A; Dong, H; Carroll, J et al. (2017) Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling. Mol Psychiatry 22:1126-1133

Showing the most recent 10 out of 318 publications